Respiri Limited announced the appointment of Dr. Andrew Weekes as a strategic advisor to the Respiri Board, effective 15 March 2021. The timing of this appointment seeks to align expert advice with additional initiatives undertaken to launch wheezoTM in the UK market in late 2021. Dr. Weekes is currently the Country Medical Director, Australia for GlaxoSmithKline and has led a number of major initiatives at GSK, including being the first pharmaceutical company in Australia to introduce a new framework for its medical education program and interactions with healthcare professionals.